TCR T-cell therapy (BioNTech/Eli Lilly)

N/A

Report date: 2025/03/20 09:41:27

Base Information

Drug NameTCR T-cell therapy (BioNTech/Eli Lilly)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiontech Se
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyBiontech Se
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A